Sign In

Login

Password

Forgot Password ? Sign Up

XP-21279 (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "XP-21279" in English language version.

refsWebsite
Global rank English rank
10nih.gov
4th place
4th place
7doi.org
2nd place
2nd place
1springer.com
274th place
309th place
1drugbank.com
low place
low place
1patsnap.com
low place
low place

doi.org (Global: 2nd place; English: 2nd place)

  • Hauser RA (2011). "Future treatments for Parkinson's disease: surfing the PD pipeline". The International Journal of Neuroscience. 121 Suppl 2: 53–62. doi:10.3109/00207454.2011.620195. PMID 22035030.
  • Ondo W (October 2014). "IPX066 , a mixed immediate/sustained-release levodopa preparation for Parkinson's disease". Expert Opinion on Pharmacotherapy. 15 (14): 2081–2085. doi:10.1517/14656566.2014.950224. PMID 25146967.
  • Freitas ME, Ruiz-Lopez M, Fox SH (November 2016). "Novel Levodopa Formulations for Parkinson's Disease". CNS Drugs. 30 (11): 1079–1095. doi:10.1007/s40263-016-0386-8. PMID 27743318.
  • Hengartner D, Fernandez HH (February 2019). "The next chapter in symptomatic Parkinson disease treatments". Parkinsonism & Related Disorders. 59. Elsevier BV: 39–48. doi:10.1016/j.parkreldis.2019.01.002. PMID 30661840.
  • Cacciatore I, Ciulla M, Marinelli L, Eusepi P, Di Stefano A (April 2018). "Advances in prodrug design for Parkinson's disease". Expert Opinion on Drug Discovery. 13 (4): 295–305. doi:10.1080/17460441.2018.1429400. PMID 29361853.
  • Markovic M, Deodhar S, Machhi J, Yeapuri P, Saleh M, J Edagwa B, et al. (February 2022). "Prodrug Therapies for Infectious and Neurodegenerative Diseases". Pharmaceutics. 14 (3): 518. doi:10.3390/pharmaceutics14030518. PMC 8953076. PMID 35335894.
  • Haddad F, Sawalha M, Khawaja Y, Najjar A, Karaman R (December 2017). "Dopamine and Levodopa Prodrugs for the Treatment of Parkinson's Disease". Molecules. 23 (1): 40. doi:10.3390/molecules23010040. PMC 5943940. PMID 29295587.

drugbank.com (Global: low place; English: low place)

go.drugbank.com

nih.gov (Global: 4th place; English: 4th place)

pubmed.ncbi.nlm.nih.gov

  • Hauser RA (2011). "Future treatments for Parkinson's disease: surfing the PD pipeline". The International Journal of Neuroscience. 121 Suppl 2: 53–62. doi:10.3109/00207454.2011.620195. PMID 22035030.
  • Ondo W (October 2014). "IPX066 , a mixed immediate/sustained-release levodopa preparation for Parkinson's disease". Expert Opinion on Pharmacotherapy. 15 (14): 2081–2085. doi:10.1517/14656566.2014.950224. PMID 25146967.
  • Freitas ME, Ruiz-Lopez M, Fox SH (November 2016). "Novel Levodopa Formulations for Parkinson's Disease". CNS Drugs. 30 (11): 1079–1095. doi:10.1007/s40263-016-0386-8. PMID 27743318.
  • Hengartner D, Fernandez HH (February 2019). "The next chapter in symptomatic Parkinson disease treatments". Parkinsonism & Related Disorders. 59. Elsevier BV: 39–48. doi:10.1016/j.parkreldis.2019.01.002. PMID 30661840.
  • Cacciatore I, Ciulla M, Marinelli L, Eusepi P, Di Stefano A (April 2018). "Advances in prodrug design for Parkinson's disease". Expert Opinion on Drug Discovery. 13 (4): 295–305. doi:10.1080/17460441.2018.1429400. PMID 29361853.
  • Markovic M, Deodhar S, Machhi J, Yeapuri P, Saleh M, J Edagwa B, et al. (February 2022). "Prodrug Therapies for Infectious and Neurodegenerative Diseases". Pharmaceutics. 14 (3): 518. doi:10.3390/pharmaceutics14030518. PMC 8953076. PMID 35335894.
  • Haddad F, Sawalha M, Khawaja Y, Najjar A, Karaman R (December 2017). "Dopamine and Levodopa Prodrugs for the Treatment of Parkinson's Disease". Molecules. 23 (1): 40. doi:10.3390/molecules23010040. PMC 5943940. PMID 29295587.

ncbi.nlm.nih.gov

pubchem.ncbi.nlm.nih.gov

patsnap.com (Global: low place; English: low place)

synapse.patsnap.com

springer.com (Global: 274th place; English: 309th place)

adisinsight.springer.com

  • "XP 21279". AdisInsight. Springer Nature Switzerland AG. 26 May 2022. Retrieved 27 September 2024.